Multiple Sclerosis 15 June 2004, vol. 10, no. Supplement 1, pp. 62-64(3)
Montalban X.
University Hospital Vall d'Hebron, Unitat de Neuroimmunologia Clinica,
E-08035, Barcelona, Spain
This short monograph describes a trial of interferon ß-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS.
Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon ß-1b 8 MIU given subcutaneously every other day for two years.
Significant differences favouring interferon ß-1b in the MSFC score, T2 lesion volume and T1 lesion volume at 24 months were observed.
Further study of interferon ß-1b therapy in PPMS patients is warranted.